India's ₹750 Weight-Loss Shot: Semaglutide Goes Generic

For the last two years, the weight-loss drugs that reshaped medicine in the West — the semaglutides and tirzepatides sold as Ozempic, Wegovy, and Mounjaro — were, for most Indians, headlines about other countries. Available, yes, but priced at ₹8,800 to ₹10,000 a month, they were out of reach for the vast majority. That wall just came down. On 20 March 2026, the patent on semaglutide expired in India, and within days the first wave of generic versions hit the market, with at least five domestic drugmakers undercutting the original price by up to 80%. Sun Pharmaceutical launched a generic semaglutide for as little as ₹750 for a weekly injection — roughly ₹3,400 a month against the originator's ₹8,800–10,000. In a country with an estimated 100 million people living with diabetes and nearly a quarter of adults classified as obese, that is not a market event. It's a public-health inflection point.

Here's what's happening, why the price collapse matters so much in India specifically, and — importantly — the cautions that come with it. None of this is medical advice; these are prescription medicines, and the decision to use them belongs with a doctor, not an article.

What these drugs are, briefly

The drugs at the center of this are GLP-1 receptor agonists (semaglutide is the best-known; tirzepatide, sold as Mounjaro, acts on related pathways). In plain terms, they mimic a gut hormone that helps regulate blood sugar and appetite. They were developed for type 2 diabetes, but their pronounced effect on appetite and weight turned them into the most significant obesity treatment in a generation. That's the what. The how much, how long, and whether at all are clinical questions that depend entirely on an individual's health — which is exactly why they're prescription drugs requiring medical supervision, not lifestyle purchases.

How India got here

The Indian rollout has moved fast over the past year, per reporting from outlets including CNBC and Business Today:

• March 2025: Eli Lilly's Mounjaro (tirzepatide) launched in India.
• A few months later: Novo Nordisk's Wegovy (semaglutide for weight loss) arrived.
• December 2025: Ozempic launched.
• October 2025: Mounjaro became India's top-selling drug by value — a stunning indicator of pent-up demand.
• 20 March 2026: Semaglutide's patent expired, opening the floodgates to generics.

That last date is the hinge. As long as the molecule was under patent, only the originator could sell it, and it priced accordingly. The moment the patent lapsed, India's famously competitive generic-pharma industry — the "pharmacy of the world" — did what it does best: it made the same molecule for a fraction of the price.

The price collapse, in numbers

	Originator (branded)	Generic (e.g. Sun Pharma)
Per weekly injection	—	as low as ~₹750
Per month	~₹8,800–10,000	~₹3,400
Price cut	—	up to ~80%

And this is just the opening wave. More than 50 brand names are expected across the Indian market through 2026, from over 40 manufacturers. When that many competitors enter, prices tend to fall further still. The market is also about to diversify in form: Novo Nordisk is preparing a pill version of semaglutide, and Eli Lilly is developing its own oral drug, orforglipron — and a pill that works as well as an injection would remove one more barrier (needle aversion) to access.

Why this matters so much in India

The scale of India's metabolic-health challenge is what makes the price collapse consequential rather than merely interesting:

• ~100 million people with diabetes. India has one of the largest diabetic populations in the world. GLP-1 drugs were created for type 2 diabetes management, and affordability directly affects how many can access them.
• Roughly a quarter of adults classified as obese, with obesity-related conditions — heart disease, certain cancers, joint problems — rising alongside.
• Cost was the binding constraint. In a price-sensitive market, the difference between ₹10,000 and ₹3,400 a month is the difference between a treatment available to a thin sliver of the affluent and one within reach of a far broader population.

An 80% price cut doesn't just trim a bill; it changes who the medicine is for. That's the public-health argument, and it's a real one.

The cautions that have to come with it

This is where responsible coverage has to slow down, because cheaper access to a powerful drug cuts both ways.

• These are not casual purchases. GLP-1 drugs are prescription medicines with real side effects (commonly gastrointestinal, and a range of considerations that depend on the individual). They require medical evaluation, supervision, and follow-up. Cheaper and more available must not become a synonym for self-medicating.
• Misuse risk rises with access. Wherever these drugs have spread, so has off-label and unsupervised use for cosmetic weight loss, grey-market sourcing, and counterfeits. Lower prices and 50-plus brands raise the importance of buying only genuine, prescribed product through legitimate channels.
• They are a tool, not a cure-all. The clinical consensus is that these medications work best alongside — not instead of — diet, activity, and broader care, and that stopping them often reverses the benefit. They manage a condition; they don't erase it.
• Quality and regulation matter. A flood of new generic brands puts the spotlight on regulatory oversight to ensure every version is safe and effective.

The single most important takeaway for any reader is the unglamorous one: if you think these drugs might be relevant to your health, the next step is a conversation with a qualified doctor — not a pharmacy counter or an online seller. This article explains a market shift; it cannot and does not tell anyone whether, how, or how much of any medicine to take.

The bigger picture: a pharma superpower flexes

The speed and scale of India's price collapse is a showcase for something India does better than almost anyone: making medicines affordable at massive scale. India is often called the "pharmacy of the world" — its generic-drug industry supplies a large share of the medicines used across developing countries and a significant chunk of the generics consumed in wealthy ones too. When a blockbuster molecule comes off patent, India's manufacturers are uniquely positioned to flood the market with low-cost versions, fast.

That capability is exactly what played out with semaglutide. The moment the patent lapsed on 20 March 2026, the machinery of competitive generic manufacturing kicked in, and prices fell roughly 80% in a matter of days — with 40-plus manufacturers and 50-plus brands lining up. This is the same dynamic that, in earlier eras, made HIV and hepatitis treatments affordable across the developing world. There's a real prospect that India's cheap GLP-1 generics won't just transform the domestic market but could eventually influence global access to these drugs, much as Indian generics have done for other essential medicines.

The demand they're meeting is enormous and growing. India is sometimes described as a diabetes capital of the world, with around 100 million people living with the disease, and obesity rising sharply — nearly a quarter of adults — as diets and lifestyles shift with urbanization and rising incomes. These aren't just statistics; they translate into a vast burden of heart disease, kidney disease, and other complications that strain families and the health system. A class of drugs that can meaningfully help manage diabetes and obesity, suddenly made affordable, lands directly on one of India's most pressing health challenges. The opportunity is correspondingly large — which is precisely why getting the safety and supervision side right matters so much.

What to watch

• How far prices fall. With 40-plus manufacturers entering, watch whether competition pushes prices below even the early ₹750-per-shot generics — and how that expands real-world access.
• The oral versions. A pill that matches the injection's effect would be a major accessibility leap. Watch Novo's oral semaglutide and Lilly's orforglipron, and their pricing in India.
• Regulation and safety. As the market floods with brands, watch how India's drug regulators ensure quality and how the medical community manages the surge in demand responsibly.
• The public-health payoff — or pitfalls. The real test is whether cheaper access translates into better-managed diabetes and obesity at population scale, or whether unsupervised and cosmetic misuse creates new problems. That balance will define whether India's "weight-loss drug moment" is a public-health win.

India's semaglutide price collapse is a genuine milestone — a case study in how generic competition can take a transformative medicine and, almost overnight, make it dramatically more affordable for a country that needs it. The promise is real: better tools against a vast diabetes and obesity burden, within reach of far more people. So is the responsibility. Powerful medicines made cheap and widely available demand more medical guidance, not less — and the difference between a public-health triumph and a wave of misuse will come down to whether that guidance keeps pace with the price cuts.

This article is general health information about a market development, not medical advice. GLP-1 medications are prescription drugs; consult a qualified doctor about your own health and any treatment.